Vasculitis & polymyalgia rheumatica
A Canadian vasculitis patient-driven survey to highlight which prednisone-related side effects matter the most
Authors' conclusion
Ranking given to some GC-related SEs may differ between patients and physicians.
Study context
- Population
- Patients with vasculitis surveyed with Vasculitis Foundation Canada, April–July 2022completed the survey
- Participants
- 97 patients
- Exposure
- GPA/MPA vs Other vasculitides
- GPA/MPAn = 53
- Other vasculitidesn = 44
- Outcome
- GC-related SE reported and ranked by patients
Methodological detailsonline questionnaire survey, patient-driven
- Online questionnaire survey
- Patient-driven
Main finding
As reported in the abstract
- Patients reporting ≥1 glucocorticoids (GC)-related SE
- All
- Patients reporting ≥11/19 pre-specified SE of interest
- 67.0%
Observational data: associations, not effects.
Further findings
GC exposure
- Duration of GC use, months (mean±SD)
- 62.7±83.7
- Still on GC
- 49.5%
- Daily dose, mg
- 8.4±6.2
Knowledge of and preference for avacopan
- Would prefer being first to take a very new medication such as avacopan instead of prednisone (similarly in both groups)
- 68%
- Had heard about avacopan: around half of GPA/MPA and one-third of others
Original publication
A Canadian vasculitis patient-driven survey to highlight which prednisone-related side effects matter the most. Clin Exp Rheumatol. Published 15 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →